Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia's Innovation Horizon: Insiders Are Optimistic And Wary

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Multinationals are dropping substantial resources in R&D in Asia, but - excluding Japan - Asian countries have yet to create a significant new drug approval, and opinions differ on when strong INDs will begin to appear out of the region

You may also be interested in...



China's Escalating Scientific Output Tempered By Quality Concerns

TOKYO - Much ink has been devoted to cover the explosion of scientific research being developed in China, but some in the pharma industry charged with identifying potential research partners are troubled with the quality of some research coming out of China

LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC074341

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel